GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » Cyclically Adjusted PS Ratio

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Cyclically Adjusted PS Ratio : (As of May. 16, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Fresh Tracks Therapeutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Fresh Tracks Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Fresh Tracks Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh Tracks Therapeutics Cyclically Adjusted PS Ratio Chart

Fresh Tracks Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.07 0.03 - -

Fresh Tracks Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fresh Tracks Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Fresh Tracks Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresh Tracks Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's Cyclically Adjusted PS Ratio falls into.



Fresh Tracks Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Fresh Tracks Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Fresh Tracks Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/129.4194*129.4194
=0.000

Current CPI (Dec. 2023) = 129.4194.

Fresh Tracks Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 87.393 99.695 113.450
201406 160.893 100.560 207.068
201409 118.690 100.428 152.954
201412 166.310 99.070 217.259
201503 170.483 99.621 221.477
201506 144.000 100.684 185.098
201509 173.000 100.392 223.022
201512 234.931 99.792 304.679
201603 158.759 100.470 204.503
201606 142.138 101.688 180.900
201609 80.061 101.861 101.721
201612 90.371 101.863 114.819
201703 91.571 102.862 115.213
201706 97.743 103.349 122.399
201709 90.000 104.136 111.852
201712 69.351 104.011 86.292
201803 10.377 105.290 12.755
201806 10.652 106.317 12.967
201809 0.681 106.507 0.828
201812 1.797 105.998 2.194
201903 85.171 107.251 102.776
201906 0.000 108.070 0.000
201909 18.200 108.329 21.743
201912 3.559 108.420 4.248
202003 5.178 108.902 6.154
202006 2.308 108.767 2.746
202009 0.227 109.815 0.268
202012 0.023 109.897 0.027
202103 0.013 111.754 0.015
202106 0.099 114.631 0.112
202109 0.071 115.734 0.079
202112 0.043 117.630 0.047
202203 0.035 121.301 0.037
202206 1.625 125.017 1.682
202209 0.167 125.227 0.173
202212 0.680 125.222 0.703
202303 0.002 127.348 0.002
202306 0.009 128.729 0.009
202309 1.343 129.860 1.338
202312 0.000 129.419 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fresh Tracks Therapeutics  (OTCPK:FRTX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Fresh Tracks Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301
Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.
Executives
Monica E. Luchi officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy officer: General Counsel and CCO C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha officer: Chief Research & Dev. Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant director 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton officer: Chief Accounting Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown director, officer: Chief Executive Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer officer: COO and Secretary 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru director C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii officer: Chief Financial Officer
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja officer: Chief Medical Officer 121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy officer: Chief Business Officer C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju director 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers officer: Chief Financial Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Headlines

From GuruFocus